Skip to main content

Table 1 Demographic and clinical characteristics of patients with recurrent angioedema (RAE) (n = 86) as well as their response to treatment and quality of life impairment as assessed by use of the Thai Angioedema Quality of Life questionnaire (AE-QoL), the Thai Dermatology Life Quality Index (DLQI), the Patient Global Assessment of Quality of Life (PGA-QoL)

From: Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change

  Values
Gender, n (%)     
 Female     69 (80.2%)
 Male     17 (19.8%)
Diagnosis, n (%)
 RAE without wheals     10 (11.6%)
 RAE with wheals     76 (88.0%)
Range of scores (total score)
 Thai AE-QoL     0–79.4 (100)
 Thai DLQI     0–23 (30)
 PGA-QoL     0–3 (4)
Disease severity of urticaria of 76 RAE patients with wheals
 Urticaria activity score over 7 days (UAS7), n (%)     
 Urticaria-free (UAS7 = 0)     18 (23.7%)
 Well-controlled CSU (UAS7 = 1–6)     13 (17.1%)
 Mild activity CSU (UAS7 = 7–15)     26 (34.2%)
 Moderate activity CSU (UAS7 16–27)     14 (18.4%)
 Severe activity CSU (UAS7 = 28–42)     5 (6.6%)
Treatment, n (%)
 H1-antihistamines     74 (86.0%)
 H1-antihistamines + prednisolone     8 (9.3%)
 H1-antihistamines + omalizumab     4 (4.7%)
Impairment of health-related quality of life using:
- PGA-QoL questionnaire, n (%) AE-QoL total value mean ± SD (median) 1st quartile 3rd quartile  
None 11.2 ± 14.2 (5.9) 0 19.1 35 (40.7%)
Mild 29.9 ± 13.2 (32.4) 20.6 38.2 31 (36.0%)
Moderate 49.3 ± 17.6 (52.2) 34.9 67.3 12 (14.0%)
Severe 46.9 ± 20.4 (42.6) 34.6 61.8 8 (9.3%)
Very severe 0 0 0 0 (0.0%)
- DLQI questionnaire, n (%)
 No effect 11.6 ± 13.6 (5.9) 0 19.9 33 (38.4%)
 Small effect 26.0 ± 15.3 (24.3) 16.9 34.6 22 (25.6%)
 Moderate effect 39.7 ± 17.3 (38.2) 33.1 49.3 13 (15.1%)
 Very large effect 42.2 ± 19 (42.6) 35.7 61.8 18 (20.9%)
 Extremely large effect 0 0 0 0 (0.0%)